CELL INTELLIGENCE · 肿瘤细胞治疗研究

Claudin 18.2 靶向：泛癌视角

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

claudin 18.2 靶向免疫疗法的靶向/非肿瘤毒性建模与应对

Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies.

靶向 claudin18.2 的 CAR-T 细胞在临床前模型中的在靶脱瘤毒性

On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models.

靶向 CLDN18.2 的装甲型 CAR-T 细胞 AZD6422 在胃癌、胰腺癌和食管癌中的临床前评价

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers.

AZD6422 在患者来源的 CLDN18.2 阳性胃肠道肿瘤小鼠模型中安全且有效。我们的数据支持进一步开展 AZD6422 用于这些癌症患者的临床开发。

靶向 Claudin-18.2 的癌症治疗：2024 ASCO 年会更新

Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.

Claudin18.2-CAR-T 细胞治疗转移性胃癌靶病灶完全缓解

Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.

表达靶向 Claudin 18.2 阳性实体瘤的 T 细胞抗原耦合器的 T 细胞的临床前开发

Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2-Positive Solid Tumors.

晚期食管癌和胃食管结合部腺癌的治疗格局演变

Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.

癌症中的 Claudins：当前与未来的治疗靶点

Claudins in Cancer: A Current and Future Therapeutic Target.

CLDN18.2 靶向治疗在胃肠道肿瘤中的应用

CLDN18.2-Targeted Therapy in Gastrointestinal Cancers.